160 related articles for article (PubMed ID: 2853675)
1. Cardiovascular responses to kappa opioid agonists in intact and adrenal demedullated rats.
Gulati A; Bhargava HN
Eur J Pharmacol; 1988 Nov; 156(2):247-57. PubMed ID: 2853675
[TBL] [Abstract][Full Text] [Related]
2. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.
Randich A; Robertson JD; Willingham T
Brain Res; 1993 Feb; 603(2):186-200. PubMed ID: 8096421
[TBL] [Abstract][Full Text] [Related]
3. Comparative hypotensive actions of three nonpeptide kappa opioid agonists on hippocampus of SHRs and normotensive WKY rats.
Zhai QZ; Ingenito AJ
J Cardiovasc Pharmacol; 1998 Jun; 31(6):806-12. PubMed ID: 9641463
[TBL] [Abstract][Full Text] [Related]
4. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.
Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
Neuroendocrinology; 1986; 42(1):82-7. PubMed ID: 3001566
[TBL] [Abstract][Full Text] [Related]
5. Further study of kappa opioids on increased urination.
Leander JD
J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
[TBL] [Abstract][Full Text] [Related]
6. Effect of kappa-opioid receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats.
Ramarao P; Jablonski HI; Rehder KR; Bhargava HN
Eur J Pharmacol; 1988 Nov; 156(2):239-46. PubMed ID: 2853674
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
Pugsley MK; Penz WP; Walker MJ; Wong TM
Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
[TBL] [Abstract][Full Text] [Related]
8. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.
Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
Neuroendocrinology; 1986; 42(1):75-81. PubMed ID: 3001565
[TBL] [Abstract][Full Text] [Related]
9. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats.
Takemori AE; Schwartz MM; Portoghese PS
J Pharmacol Exp Ther; 1988 Dec; 247(3):971-4. PubMed ID: 2849679
[TBL] [Abstract][Full Text] [Related]
10. Differential antagonism of the rate-decreasing effects of kappa-opioid receptor agonists by naltrexone and norbinaltorphimine.
Powell KR; Holtzman SG
Eur J Pharmacol; 1999 Jul; 377(1):21-8. PubMed ID: 10448921
[TBL] [Abstract][Full Text] [Related]
11. Bremazocine differentially antagonizes responses to selective mu and delta opioid receptor agonists in rat hippocampus.
Dunwiddie TV; Johnson KJ; Proctor WR
Br J Pharmacol; 1987 Jul; 91(3):523-30. PubMed ID: 3038241
[TBL] [Abstract][Full Text] [Related]
12. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
13. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
Picker MJ; Dykstra LA
J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
[TBL] [Abstract][Full Text] [Related]
15. Effects of kappa-opioid receptor agonists and morphine on food intake and urinary output in food-deprived and nondeprived rats.
Ramarao P; Bhargava HN
Pharmacol Biochem Behav; 1989 Jun; 33(2):375-80. PubMed ID: 2554341
[TBL] [Abstract][Full Text] [Related]
16. Effect of mu and kappa opioid receptor agonists on rat plasma corticosterone levels.
Hayes AG; Stewart BR
Eur J Pharmacol; 1985 Oct; 116(1-2):75-9. PubMed ID: 2996912
[TBL] [Abstract][Full Text] [Related]
17. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse.
Horan PJ; de Costa BR; Rice K; Haaseth RC; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1993 Aug; 266(2):926-33. PubMed ID: 8394923
[TBL] [Abstract][Full Text] [Related]
18. Roles of central and peripheral mu, delta and kappa opioid receptors in the mediation of gastric acid secretory effects in the rat.
Fox DA; Burks TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):456-62. PubMed ID: 2831341
[TBL] [Abstract][Full Text] [Related]
19. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
20. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.
Nestby P; Schoffelmeer AN; Homberg JR; Wardeh G; De Vries TJ; Mulder AH; Vanderschuren LJ
Psychopharmacology (Berl); 1999 Mar; 142(3):309-17. PubMed ID: 10208324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
